1-(4-bromophenyl)ethanol is an organic compound with the chemical formula C8H9BrO. It is a colorless liquid that is insoluble in water.
**Structure and Properties:**
* **Structure:** It consists of a benzene ring with a bromine atom at the para position (opposite to the hydroxyl group) and an ethanol group attached to the ring.
* **Properties:** It is a chiral molecule, meaning it exists in two enantiomeric forms. It is also known to be a potential precursor for the synthesis of various pharmaceuticals and other organic compounds.
**Importance in Research:**
1-(4-bromophenyl)ethanol is a valuable compound in research due to its versatility as a building block for various organic syntheses. Its key applications include:
* **Pharmaceutical Research:** It serves as a precursor for synthesizing pharmaceuticals with diverse biological activities.
* **Material Science:** Its structure and properties make it suitable for the development of novel materials with specific applications.
* **Catalyst Development:** It can be used as a catalyst in various chemical reactions, including organic transformations.
* **Biochemistry and Drug Discovery:** Studying its interactions with biological targets can lead to the development of new drugs and therapies.
**Specific Examples:**
* **Synthesis of Chiral Pharmaceuticals:** 1-(4-bromophenyl)ethanol can be used to synthesize chiral pharmaceuticals, which are essential for treating various diseases.
* **Development of New Materials:** It can be used to create new materials with unique properties, such as improved conductivity or enhanced mechanical strength.
* **Study of Enzyme Activity:** It can be used as a substrate to study the activity of specific enzymes involved in metabolic pathways.
**Overall, 1-(4-bromophenyl)ethanol is a versatile compound that holds great potential for advancements in various fields of research, particularly in pharmaceuticals, materials science, and biochemistry.**
1-(4-bromophenyl)ethanol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 95352 |
| SCHEMBL ID | 743489 |
| MeSH ID | M0513205 |
| Synonym |
|---|
| p-bromophenylmethylcarbinol |
| F2189-0065 |
| 5391-88-8 |
| nsc-3223 |
| nsc3223 |
| benzyl alcohol, p-bromo-.alpha.-methyl- |
| benzenemethanol, 4-bromo-.alpha.-methyl- |
| 4-bromo-alpha-methylbenzyl alcohol, 97% |
| 1-(4-bromophenyl)ethyl alcohol |
| 4-bromo-alpha-methylbenzyl alcohol |
| 1-(4-bromophenyl)ethanol |
| B1955 |
| AKOS000249110 |
| FT-0659041 |
| FT-0651014 |
| inchi=1/c8h9bro/c1-6(10)7-2-4-8(9)5-3-7/h2-6,10h,1h3 |
| xtdtysbvmbqibt-uhfffaoysa- |
| 1-(4-bromophenyl)ethan-1-ol |
| EN300-56126 |
| 4-bromo-a-methylbenzyl alcohol |
| 4-bromophenylmethylcarbinol |
| 4-bromophenyl methyl carbinol |
| benzenemethanol, 4-bromo-alpha-methyl- |
| ai3-11017 |
| einecs 226-389-9 |
| nsc 3223 |
| FT-0605663 |
| SCHEMBL743489 |
| 1-(4-bromo-phenyl)-ethanol |
| 4-bromo-methylbenzyl alcohol |
| p-bromo-alpha-methylbenzyl alcohol |
| 4-bromo-alpha-methylbenzylalcohol |
| (+/-)-1-(4-bromophenyl)ethanol |
| 4-bromo-methylbenzylalcohol |
| p-bromophenylethanol |
| 1-(p-bromophenyl)ethanol |
| AKOS016050372 |
| 4-bromo-.alpha.-methylbenzenemethanol |
| p-bromo-.alpha.-methylbenzyl alcohol |
| 4-bromo-.alpha.-methylbenzylalcohol |
| p-bromophenyl methyl carbinol |
| AM87046 |
| W-105696 |
| mfcd00004514 |
| F16011 |
| SY024772 |
| SY024771 |
| SY005047 |
| DS-4797 |
| (s)-3-((s)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoicacid |
| CS-0099410 |
| p-bromo-alpha-methyl-benzyl alcohol |
| DTXSID301034356 |
| 4-bromo- alpha -methylbenzyl alcohol |
| Z335244904 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.69) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||